Evenity (Romosozumab) Adolescent (12-17) Dosing

Regulatory Status and Why No Pediatric Approval Exists

Romosozumab received FDA approval in April 2019 for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture or multiple risk factors, or patients who have failed other available therapies [2]. The drug carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death.

Amgen/UCB have not submitted a supplemental New Drug Application for any pediatric population. The reasons are both biological and regulatory. Sclerostin, the protein target of romosozumab, plays an active role in endochondral ossification during skeletal growth [3]. Animal studies in young cynomolgus monkeys showed increased bone formation but also premature physeal closure at supratherapeutic doses. The FDA's 2019 approval review specifically noted that "the safety and effectiveness of Evenity in pediatric patients have not been established" and that juvenile animal toxicity studies raised concerns about effects on growing bone [2].

No Pediatric Research Equity Act (PREA) requirement was triggered because the approved indication (postmenopausal osteoporosis) does not have a pediatric analog. Without a Written Request from the FDA or a voluntary pediatric study plan from the manufacturer, formal dose-finding trials in adolescents remain absent from the ClinicalTrials.gov registry as of May 2026.

Mechanism of Action and Growth Plate Biology

Romosozumab binds and inhibits sclerostin, a glycoprotein produced primarily by osteocytes that suppresses the Wnt signaling pathway [4]. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption. This dual effect produced the rapid bone mineral density (BMD) gains observed in adult trials: lumbar spine BMD increased 13.3% over 12 months in the FRAME trial (N=7,180) [5].

The concern for adolescents centers on where sclerostin is expressed beyond mature osteocytes. Research published in the Journal of Bone and Mineral Research demonstrated sclerostin expression in hypertrophic chondrocytes of the growth plate [3]. These cells regulate the transition zone between cartilage and mineralized bone during longitudinal growth. Blocking sclerostin in a skeleton that has not reached full maturity could theoretically accelerate growth plate fusion, alter final adult height, or produce asymmetric bone formation.

In sclerosteosis and van Buchem disease (genetic conditions with absent or reduced sclerostin), patients develop progressive bone overgrowth beginning in childhood [6]. While these conditions confirm that sclerostin loss increases bone mass, the skeletal overgrowth phenotype (including cranial nerve entrapment and increased intracranial pressure) illustrates the risks of unopposed Wnt activation in growing bone.

Off-Label Clinical Scenarios Where Adolescent Use Has Been Considered

Pediatric endocrinologists and orthopedists have discussed romosozumab in clinical case conferences for a narrow subset of adolescent patients. These include:

Osteogenesis imperfecta (OI) type III/IV with recurrent fractures despite bisphosphonate therapy. A 2023 case series from Great Ormond Street Hospital described three adolescents aged 14-16 with severe OI who received romosozumab after failing both pamidronate and denosumab [7]. BMD Z-scores improved by 1.2 to 1.8 SD over 12 months, but the series was uncontrolled and follow-up was limited to 18 months.

Immobilization osteoporosis from spinal cord injury. Adolescents with complete thoracic SCI lose 25-40% of distal femur BMD within the first two years post-injury [8]. The rapid bone loss exceeds what bisphosphonates can prevent, and some rehabilitation centers have considered anabolic agents.

Iatrogenic osteoporosis from chronic glucocorticoid use. Adolescents with severe lupus nephritis, inflammatory bowel disease, or Duchenne muscular dystrophy on long-term prednisone (≥7.5 mg/day for >3 months) develop fragility fractures at rates approaching 30% in some cohorts [9].

What Would Adolescent Dosing Look Like Based on Pharmacokinetic Extrapolation

No published pediatric pharmacokinetic (PK) study for romosozumab exists. Any dosing discussion must rely on PK principles extrapolated from adult data and body-weight scaling.

In adults, romosozumab 210 mg subcutaneous monthly produces steady-state trough concentrations of approximately 7-22 mcg/mL [10]. The drug displays nonlinear, target-mediated disposition: clearance decreases at higher concentrations as sclerostin binding sites become saturated. Body weight is the most significant covariate affecting exposure. In adult analyses, patients weighing <60 kg had approximately 20-30% higher area-under-the-curve (AUC) values than patients weighing >90 kg.

For a 50 kg adolescent, allometric scaling (using the 0.75 power rule for clearance) would predict a weight-adjusted dose of approximately 140-170 mg monthly to achieve comparable adult exposures. However, this calculation ignores the fundamentally different bone biology of an adolescent. Higher baseline bone turnover in growing patients (serum P1NP values 3-5 times adult reference ranges) means the drug would operate in a different pharmacodynamic context. The therapeutic window, if one exists for this population, is unknown.

The adult fixed dose of 210 mg is delivered as two separate 105 mg/1.17 mL subcutaneous injections. Any investigational use in adolescents would likely require a reduced volume and concentration, which would require either dilution (not validated) or a reformulated product.

Safety Concerns Specific to Adolescents

The boxed warning for cardiovascular events deserves particular attention. In the ARCH trial, romosozumab-treated patients had a 2.5% rate of adjudicated major adverse cardiovascular events (MACE) at 12 months compared to 1.9% in the alendronate arm (HR 1.31 to 95% CI 0.85-2.00) [1]. While adolescents generally have low baseline cardiovascular risk, the concern shifts to:

Subclinical vascular calcification. Romosozumab increased Wnt signaling in vascular smooth muscle cells in preclinical studies, and sclerostin may serve a protective role against vascular calcification [11]. In adolescents with chronic kidney disease (who already face accelerated vascular aging), this mechanism could be particularly hazardous.

Hypersensitivity and immunogenicity. Anti-drug antibodies (ADAs) developed in 18% of adult patients in clinical trials, with neutralizing antibodies in 3.2% [2]. Pediatric immune systems may mount more vigorous humoral responses to therapeutic monoclonal antibodies, potentially increasing immunogenicity rates.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). While rates were low in adult trials (<0.1%), the long-term risk in patients who receive romosozumab during adolescence and then require decades of subsequent antiresorptive therapy is completely unstudied.

Rebound bone loss on discontinuation. Adult studies show rapid BMD decline after completing 12 months of romosozumab if no antiresorptive is given sequentially [12]. In an adolescent whose skeleton is still consolidating peak bone mass, the rebound could be more severe and clinically significant.

How This Compares to Other Bone Anabolic Agents in Pediatrics

Teriparatide (Forteo), another bone-forming agent, carried a boxed warning against use in patients with open epiphyses due to osteosarcoma risk observed in rats exposed to PTH(1-34) for near-lifetime durations [13]. That warning made teriparatide contraindicated in essentially all pediatric patients. The osteosarcoma signal was not replicated in the 15-year post-marketing surveillance study (OSTEOSARCOMA surveillance study, completed 2021), but the label restriction remains.

Romosozumab does not share the osteosarcoma concern. No signal appeared in preclinical carcinogenicity studies or adult post-marketing data. This distinction matters because it means romosozumab's barrier to pediatric exploration is not a cancer safety signal but rather the cardiovascular warning and growth plate uncertainties.

Denosumab (Prolia/Xgeva) has more pediatric clinical experience, particularly in giant cell tumor of bone and fibrous dysplasia in adolescents. However, denosumab's severe rebound vertebral fractures on discontinuation have been well-documented [14], and the pediatric experience has revealed growth plate abnormalities including sclerotic bands visible on plain radiographs.

Monitoring Framework If Off-Label Use Proceeds

For the rare clinical situation where a multidisciplinary team determines that romosozumab is the only remaining option for an adolescent with life-threatening skeletal fragility, published expert opinion suggests the following monitoring approach:

Before initiating: Baseline DXA (spine and total body less head), lateral spine radiograph for vertebral fracture assessment, left hand bone age, Tanner staging, serum calcium, 25-hydroxyvitamin D, P1NP, CTX, complete metabolic panel, and lipid panel. Echocardiogram and carotid intima-media thickness if any cardiovascular risk factors are present.

Monthly: Injection-site assessment, vital signs, and symptom review for chest pain or neurological symptoms.

Every 3 months: Serum P1NP (to confirm anabolic response), CTX, calcium, and growth velocity measurement.

Every 6 months: Repeat bone age if Tanner stage <V, repeat DXA at 6 and 12 months.

At treatment completion: Immediate transition to an antiresorptive agent (typically a bisphosphonate with pediatric dosing data such as zoledronic acid 0.05 mg/kg IV annually) to prevent rebound bone loss [12].

What Clinical Trials Would Be Needed

The pathway to an approved pediatric indication would require, at minimum:

A phase I/II open-label dose-escalation study in adolescents aged 14-17 (post-peak height velocity) with severe secondary osteoporosis who have failed standard therapy. Primary endpoints would be safety, PK, and BMD change at 6 and 12 months. Growth velocity and bone age would be mandatory secondary endpoints.

The Endocrine Society's 2020 guidelines on pediatric bone health noted that "there is an unmet need for anabolic bone therapies in children with severe skeletal fragility syndromes, and regulatory incentives should encourage industry-sponsored trials" [15]. Despite this position statement, no sponsor has initiated such work.

Given the rarity of the target population (adolescents with severe osteoporosis refractory to bisphosphonates), any trial would likely require a global consortium design similar to the approach used for pediatric denosumab studies in osteogenesis imperfecta (the TOPAZ trial, NCT04638153).

Current Clinical Guidance

The American College of Rheumatology's 2022 guideline for glucocorticoid-induced osteoporosis does not address patients under 18 [16]. The Endocrine Society's guidelines reference teriparatide and romosozumab only in adult populations. No major pediatric society has issued a position statement specifically addressing romosozumab in minors.

In practice, adolescent patients with severe osteoporosis are managed with intravenous bisphosphonates (pamidronate or zoledronic acid), adequate calcium and vitamin D repletion, physical therapy, and treatment of the underlying cause. For osteogenesis imperfecta specifically, cyclic pamidronate remains the standard of care based on decades of observational data showing reduced fracture rates and improved mobility [17].

Romosozumab in adolescents aged 12-17 remains investigational with no published dosing protocol, no pharmacokinetic data, and no randomized controlled trial evidence. Any off-label use should occur only at specialized pediatric bone centers, with institutional review board oversight, informed consent addressing the unknown long-term risks, and a pre-specified monitoring and discontinuation plan. The adult dose of 210 mg monthly for 12 months cannot be directly applied to this population without formal study.